Chordoma and chondrosarcoma: Similar, but quite different, skull base tumors
BACKGROUND Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings. The chondroid chordoma variant has been reported to carry a better prognosis. The objective of the current study was to investigat...
Saved in:
Published in | Cancer Vol. 110; no. 11; pp. 2467 - 2477 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.12.2007
Wiley-Liss |
Subjects | |
Online Access | Get full text |
ISSN | 0008-543X 1097-0142 |
DOI | 10.1002/cncr.23073 |
Cover
Abstract | BACKGROUND
Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings. The chondroid chordoma variant has been reported to carry a better prognosis. The objective of the current study was to investigate the distinctions between these 3 entities.
METHODS
The data concerning 109 patients with chordoma, chondroid chordoma, and chondrosarcoma who were treated by a single surgeon with maximum surgical resection and frequently by adjunct proton beam radiotherapy between 1990 and 2006 were analyzed retrospectively. Pathologic distinction was established by cytokeratin and epithelial membrane antigen staining. Clinical, radiologic, pathologic, and cytogenetic studies were analyzed in relation to disease recurrence and death.
RESULTS
The average follow‐up was 48 ± 37.5 months (range, 1–191 months). There were no reliable distinguishing clinical or radiologic features noted between the groups. Chondrosarcoma patients had a significantly better outcome compared with chordoma patients with regard to survival and recurrence‐free survival (P = .028 and P < .001, respectively), whereas patients with chondroid chordoma had a poor outcome similar to chordoma patients with regard to survival and recurrence‐free survival (P = .337 and P = .906, respectively).
CONCLUSIONS
Chordoma and chondrosarcoma differ with regard to their origin and histology, and differ markedly with regard to outcome. Chondroid chordomas behave in a manner that is clinically similar to chordomas, with the same prognosis. Both chordoma types demonstrate an aggressive clinical course and poor outcome after disease recurrence. The optimal treatment for all groups of patients involves radical surgical resection followed by high‐dose radiotherapy in patients with chordomas. Radiotherapy may not be necessary in patients with low‐grade chondrosarcoma. Cancer 2007. © 2007 American Cancer Society.
Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings. However, these tumors differ with regard to origin and histology, and differ markedly in outcome. Chondroid chordoma carries the same poor prognosis as chordoma. The optimal treatment for all groups involves radical resection followed by high‐dose radiotherapy in patients with chordoma. Radiotherapy may not be necessary in patients with low‐grade chondrosarcoma. |
---|---|
AbstractList | BACKGROUND
Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings. The chondroid chordoma variant has been reported to carry a better prognosis. The objective of the current study was to investigate the distinctions between these 3 entities.
METHODS
The data concerning 109 patients with chordoma, chondroid chordoma, and chondrosarcoma who were treated by a single surgeon with maximum surgical resection and frequently by adjunct proton beam radiotherapy between 1990 and 2006 were analyzed retrospectively. Pathologic distinction was established by cytokeratin and epithelial membrane antigen staining. Clinical, radiologic, pathologic, and cytogenetic studies were analyzed in relation to disease recurrence and death.
RESULTS
The average follow‐up was 48 ± 37.5 months (range, 1–191 months). There were no reliable distinguishing clinical or radiologic features noted between the groups. Chondrosarcoma patients had a significantly better outcome compared with chordoma patients with regard to survival and recurrence‐free survival (P = .028 and P < .001, respectively), whereas patients with chondroid chordoma had a poor outcome similar to chordoma patients with regard to survival and recurrence‐free survival (P = .337 and P = .906, respectively).
CONCLUSIONS
Chordoma and chondrosarcoma differ with regard to their origin and histology, and differ markedly with regard to outcome. Chondroid chordomas behave in a manner that is clinically similar to chordomas, with the same prognosis. Both chordoma types demonstrate an aggressive clinical course and poor outcome after disease recurrence. The optimal treatment for all groups of patients involves radical surgical resection followed by high‐dose radiotherapy in patients with chordomas. Radiotherapy may not be necessary in patients with low‐grade chondrosarcoma. Cancer 2007. © 2007 American Cancer Society.
Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings. However, these tumors differ with regard to origin and histology, and differ markedly in outcome. Chondroid chordoma carries the same poor prognosis as chordoma. The optimal treatment for all groups involves radical resection followed by high‐dose radiotherapy in patients with chordoma. Radiotherapy may not be necessary in patients with low‐grade chondrosarcoma. Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings. The chondroid chordoma variant has been reported to carry a better prognosis. The objective of the current study was to investigate the distinctions between these 3 entities. The data concerning 109 patients with chordoma, chondroid chordoma, and chondrosarcoma who were treated by a single surgeon with maximum surgical resection and frequently by adjunct proton beam radiotherapy between 1990 and 2006 were analyzed retrospectively. Pathologic distinction was established by cytokeratin and epithelial membrane antigen staining. Clinical, radiologic, pathologic, and cytogenetic studies were analyzed in relation to disease recurrence and death. The average follow-up was 48+/-37.5 months (range, 1-191 months). There were no reliable distinguishing clinical or radiologic features noted between the groups. Chondrosarcoma patients had a significantly better outcome compared with chordoma patients with regard to survival and recurrence-free survival (P=.028 and P<.001, respectively), whereas patients with chondroid chordoma had a poor outcome similar to chordoma patients with regard to survival and recurrence-free survival (P=.337 and P=.906, respectively). Chordoma and chondrosarcoma differ with regard to their origin and histology, and differ markedly with regard to outcome. Chondroid chordomas behave in a manner that is clinically similar to chordomas, with the same prognosis. Both chordoma types demonstrate an aggressive clinical course and poor outcome after disease recurrence. The optimal treatment for all groups of patients involves radical surgical resection followed by high-dose radiotherapy in patients with chordomas. Radiotherapy may not be necessary in patients with low-grade chondrosarcoma. Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings. The chondroid chordoma variant has been reported to carry a better prognosis. The objective of the current study was to investigate the distinctions between these 3 entities.BACKGROUNDChordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings. The chondroid chordoma variant has been reported to carry a better prognosis. The objective of the current study was to investigate the distinctions between these 3 entities.The data concerning 109 patients with chordoma, chondroid chordoma, and chondrosarcoma who were treated by a single surgeon with maximum surgical resection and frequently by adjunct proton beam radiotherapy between 1990 and 2006 were analyzed retrospectively. Pathologic distinction was established by cytokeratin and epithelial membrane antigen staining. Clinical, radiologic, pathologic, and cytogenetic studies were analyzed in relation to disease recurrence and death.METHODSThe data concerning 109 patients with chordoma, chondroid chordoma, and chondrosarcoma who were treated by a single surgeon with maximum surgical resection and frequently by adjunct proton beam radiotherapy between 1990 and 2006 were analyzed retrospectively. Pathologic distinction was established by cytokeratin and epithelial membrane antigen staining. Clinical, radiologic, pathologic, and cytogenetic studies were analyzed in relation to disease recurrence and death.The average follow-up was 48+/-37.5 months (range, 1-191 months). There were no reliable distinguishing clinical or radiologic features noted between the groups. Chondrosarcoma patients had a significantly better outcome compared with chordoma patients with regard to survival and recurrence-free survival (P=.028 and P<.001, respectively), whereas patients with chondroid chordoma had a poor outcome similar to chordoma patients with regard to survival and recurrence-free survival (P=.337 and P=.906, respectively).RESULTSThe average follow-up was 48+/-37.5 months (range, 1-191 months). There were no reliable distinguishing clinical or radiologic features noted between the groups. Chondrosarcoma patients had a significantly better outcome compared with chordoma patients with regard to survival and recurrence-free survival (P=.028 and P<.001, respectively), whereas patients with chondroid chordoma had a poor outcome similar to chordoma patients with regard to survival and recurrence-free survival (P=.337 and P=.906, respectively).Chordoma and chondrosarcoma differ with regard to their origin and histology, and differ markedly with regard to outcome. Chondroid chordomas behave in a manner that is clinically similar to chordomas, with the same prognosis. Both chordoma types demonstrate an aggressive clinical course and poor outcome after disease recurrence. The optimal treatment for all groups of patients involves radical surgical resection followed by high-dose radiotherapy in patients with chordomas. Radiotherapy may not be necessary in patients with low-grade chondrosarcoma.CONCLUSIONSChordoma and chondrosarcoma differ with regard to their origin and histology, and differ markedly with regard to outcome. Chondroid chordomas behave in a manner that is clinically similar to chordomas, with the same prognosis. Both chordoma types demonstrate an aggressive clinical course and poor outcome after disease recurrence. The optimal treatment for all groups of patients involves radical surgical resection followed by high-dose radiotherapy in patients with chordomas. Radiotherapy may not be necessary in patients with low-grade chondrosarcoma. |
Author | Colli, Benedicto O. Gokden, Murat Al‐Mefty, Ossama Pravdenkova, Svetlana Almefty, Kaith |
Author_xml | – sequence: 1 givenname: Kaith surname: Almefty fullname: Almefty, Kaith – sequence: 2 givenname: Svetlana surname: Pravdenkova fullname: Pravdenkova, Svetlana – sequence: 3 givenname: Benedicto O. surname: Colli fullname: Colli, Benedicto O. – sequence: 4 givenname: Ossama surname: Al‐Mefty fullname: Al‐Mefty, Ossama email: keelandamye@uams.edu – sequence: 5 givenname: Murat surname: Gokden fullname: Gokden, Murat |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19689911$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17894390$$D View this record in MEDLINE/PubMed |
BookMark | eNp90UtrFTEYBuAgFXta3fgDJBu7kE7NdWbiToZ6gUMFL-AufJMLjWaSNpmh9N936jkqiHQVEp73g3zvETpIOTmEnlNyRglhr00y5Yxx0vFHaEOJ6hpCBTtAG0JI30jBvx-io1p_rNeOSf4EHdKuV4IrskHb4TIXmyfAkCw2lznZkisUsz69wV_CFCKUUzwuM75ewuywDd674tJ8iuvPJUY8QnV4XqZc6lP02EOs7tn-PEbf3p1_HT4020_vPw5vt40RjPPGKuE7CURyy1tKVaeMZdKOqrW9B-i4sCNTigmmvAdvnVRj16p2HGXPpRf8GJ3s5l6VfL24OuspVONihOTyUnXbS9H2pF3hiz1cxslZfVXCBOVW__7_Cl7uAVQD0RdIJtS_TrW9UpSujuycWbdTi_PahBnmkNNcIERNib6vQt9XoX9VsUZe_RP5M_V_mO7wTYju9gGph4vh8y5zB-aDmIo |
CODEN | CANCAR |
CitedBy_id | crossref_primary_10_1016_j_gene_2016_03_032 crossref_primary_10_1007_s00701_024_06241_5 crossref_primary_10_25259_JCIS_186_2021 crossref_primary_10_3389_fneur_2020_00657 crossref_primary_10_1016_j_clon_2018_01_002 crossref_primary_10_1016_S1639_870X_22_47240_0 crossref_primary_10_1002_cncr_31958 crossref_primary_10_1038_s41419_018_0738_z crossref_primary_10_1007_s10143_010_0263_8 crossref_primary_10_1371_journal_pone_0309686 crossref_primary_10_1007_s11060_011_0559_8 crossref_primary_10_3389_fonc_2021_733088 crossref_primary_10_1186_s12957_021_02178_6 crossref_primary_10_1007_s10014_017_0283_y crossref_primary_10_1016_j_wneu_2014_08_049 crossref_primary_10_1093_neuros_nyx254 crossref_primary_10_1007_s11060_013_1211_6 crossref_primary_10_1007_s11060_010_0184_y crossref_primary_10_1177_19714009211055195 crossref_primary_10_1007_s10143_009_0235_z crossref_primary_10_1016_j_wneu_2022_03_088 crossref_primary_10_1093_ons_opaa091 crossref_primary_10_1038_modpathol_2008_144 crossref_primary_10_1016_S1879_8551_11_70852_1 crossref_primary_10_1016_j_wneu_2014_07_005 crossref_primary_10_1097_MD_0000000000011274 crossref_primary_10_1007_s11060_020_03511_x crossref_primary_10_1016_j_canep_2024_102527 crossref_primary_10_1016_S1286_935X_21_44904_X crossref_primary_10_1053_j_ro_2023_03_004 crossref_primary_10_1007_s00234_024_03322_1 crossref_primary_10_1016_j_ijrobp_2018_01_060 crossref_primary_10_1016_j_wneu_2018_07_153 crossref_primary_10_1093_ons_opx020 crossref_primary_10_1007_s10014_012_0085_1 crossref_primary_10_1016_j_jocn_2021_04_037 crossref_primary_10_1007_s12105_019_01091_5 crossref_primary_10_1097_SCS_0000000000003859 crossref_primary_10_1016_j_path_2016_11_003 crossref_primary_10_3174_ajnr_A7607 crossref_primary_10_1016_j_ctrv_2011_04_005 crossref_primary_10_1016_j_ijrobp_2011_08_004 crossref_primary_10_1016_j_nic_2018_09_007 crossref_primary_10_1016_j_wneu_2017_10_054 crossref_primary_10_1016_j_mric_2025_01_002 crossref_primary_10_1593_neo_13150 crossref_primary_10_1007_s13402_019_00454_y crossref_primary_10_1093_nop_npae040 crossref_primary_10_1007_s00701_017_3266_1 crossref_primary_10_1007_s00701_023_05837_7 crossref_primary_10_1007_s11060_020_03569_7 crossref_primary_10_1016_j_wjorl_2015_09_005 crossref_primary_10_3171_2022_1_JNS212703 crossref_primary_10_1093_ons_opab336 crossref_primary_10_1016_j_otc_2015_02_009 crossref_primary_10_1016_j_neuchi_2014_02_003 crossref_primary_10_3389_fonc_2022_865865 crossref_primary_10_2350_10_07_0875_PB_1 crossref_primary_10_1148_rg_240036 crossref_primary_10_1007_s00701_017_3163_7 crossref_primary_10_1227_NEU_0b013e3182446783 crossref_primary_10_1016_j_wneu_2019_01_119 crossref_primary_10_1016_j_yacr_2024_04_014 crossref_primary_10_3389_fonc_2024_1376622 crossref_primary_10_31986_issn_2578_3343_vol2iss1_4 crossref_primary_10_1016_j_neucir_2018_03_004 crossref_primary_10_17650_2070_9781_2021_13_1_32_40 crossref_primary_10_1093_ons_opab043 crossref_primary_10_1148_rg_2019180122 crossref_primary_10_3389_fonc_2024_1380716 crossref_primary_10_1016_j_wneu_2018_02_127 crossref_primary_10_1007_s00701_017_3409_4 crossref_primary_10_1177_1971400915609341 crossref_primary_10_1097_CAD_0000000000001327 crossref_primary_10_1007_s10143_011_0334_5 crossref_primary_10_3171_2018_10_JNS182154 crossref_primary_10_1177_000348941312201206 crossref_primary_10_1007_s00117_008_1802_y crossref_primary_10_1007_s00405_015_3513_0 crossref_primary_10_1016_j_neurol_2009_06_001 crossref_primary_10_1016_j_ijrobp_2022_02_024 crossref_primary_10_1016_j_jocn_2021_12_018 crossref_primary_10_1093_neuros_nyx042 crossref_primary_10_1016_j_neucie_2018_03_001 crossref_primary_10_1016_j_wneu_2019_04_086 crossref_primary_10_1007_s12105_017_0860_8 crossref_primary_10_3390_diagnostics14020200 crossref_primary_10_1007_s13244_018_0643_0 crossref_primary_10_1007_s11282_014_0184_2 crossref_primary_10_1016_j_ijrobp_2015_12_016 crossref_primary_10_3171_2017_1_JNS162000 crossref_primary_10_1155_2011_953047 crossref_primary_10_1227_ons_0000000000001429 crossref_primary_10_1007_s10143_021_01576_4 crossref_primary_10_14791_btrt_2024_0010 crossref_primary_10_3390_cancers14040966 crossref_primary_10_1007_s40134_018_0275_7 crossref_primary_10_1016_S1639_870X_13_66027_4 crossref_primary_10_1007_s00256_019_03228_7 crossref_primary_10_1016_j_ctro_2024_100814 crossref_primary_10_1016_S1632_3475_22_47147_5 crossref_primary_10_1016_j_clineuro_2019_01_017 crossref_primary_10_1186_s12885_018_4291_z crossref_primary_10_1155_2012_861217 crossref_primary_10_1016_S1879_8551_09_70829_2 crossref_primary_10_1007_s00405_024_08864_x crossref_primary_10_1016_j_rpor_2014_09_002 crossref_primary_10_1016_j_clon_2010_09_011 crossref_primary_10_1093_neuros_nyw013 crossref_primary_10_1007_s11912_024_01506_9 crossref_primary_10_1016_j_ijrobp_2024_09_030 crossref_primary_10_2176_nmccrj_cr_2019_0136 crossref_primary_10_1016_j_otc_2014_12_008 crossref_primary_10_3390_cancers16142569 crossref_primary_10_1016_j_wneu_2020_03_192 crossref_primary_10_1016_j_currproblcancer_2013_07_007 crossref_primary_10_1016_j_jocn_2014_02_005 crossref_primary_10_1016_j_wneu_2017_10_013 crossref_primary_10_1227_neu_0000000000002488 crossref_primary_10_1227_ONS_0000000000000001 crossref_primary_10_1007_s00701_021_04768_5 crossref_primary_10_1016_j_spinee_2021_04_021 crossref_primary_10_5935_1808_8694_20130138 crossref_primary_10_2147_OTT_S252195 crossref_primary_10_1111_jne_12995 crossref_primary_10_17116_neiro202488031111 crossref_primary_10_1093_ons_opaa445 crossref_primary_10_1007_s00701_017_3287_9 crossref_primary_10_3174_ajnr_A3333 crossref_primary_10_1016_j_jocn_2018_04_020 crossref_primary_10_1038_s41598_020_79894_8 crossref_primary_10_1155_2014_168698 crossref_primary_10_3390_bioengineering9100537 crossref_primary_10_1007_s11102_008_0116_4 crossref_primary_10_1111_cpr_12388 crossref_primary_10_1007_s11060_021_03764_0 crossref_primary_10_1016_j_adro_2024_101582 crossref_primary_10_1097_01_CNE_0000315852_78075_89 crossref_primary_10_1177_0284185115574156 crossref_primary_10_1007_s11060_020_03464_1 crossref_primary_10_1016_j_ijrobp_2016_01_057 crossref_primary_10_1093_ons_opx171 crossref_primary_10_3390_brainsci12101353 |
Cites_doi | 10.3109/17453678108991758 10.1227/01.NEU.0000194834.74873.FB 10.1136/jnnp.65.1.88 10.3171/jns.1993.78.5.0741 10.1016/j.ijrobp.2005.02.023 10.1227/00006123-199505000-00001 10.1148/radiology.184.1.1609064 10.1016/S0009-9260(68)80019-4 10.1023/A:1008947301735 10.3171/foc.2001.10.3.6 10.1097/00000478-199911000-00007 10.1148/rg.234025176 10.1097/00000478-198406000-00005 10.1016/B978-0-7216-8148-1.50051-6 10.1023/B:NEON.0000024728.72998.7d 10.1002/1097-0142(19850701)56:1<182::AID-CNCR2820560131>3.0.CO;2-J 10.1002/1097-0142(19941015)74:8<2261::AID-CNCR2820740809>3.0.CO;2-0 10.1227/01.NEU.0000223441.51012.9D 10.1038/sj.eye.6700339 10.1002/(SICI)1097-0142(20000501)88:9<2181::AID-CNCR26>3.0.CO;2-6 10.1097/01.blo.0000174686.70003.e0 10.1227/00006123-198511000-00002 10.1097/01.cco.0000129678.72521.e5 10.1097/00000478-199307000-00012 10.1093/ajcp/101.1.36 10.1093/ajcp/53.4.544 10.1007/BF00691094 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B 10.1007/s00432-004-0648-6 10.3171/foc.2001.10.3.12 10.1002/1097-0142(196405)17:5<643::AID-CNCR2820170513>3.0.CO;2-Q 10.3171/jns.1999.91.3.0432 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S 10.3171/jns.2001.95.6.0933 10.1227/01.NEU.0000215892.65663.54 10.1002/gcc.10012 10.1007/s00066-003-1065-5 |
ContentType | Journal Article |
Copyright | Copyright © 2007 American Cancer Society 2008 INIST-CNRS Copyright (c) 2007 American Cancer Society. |
Copyright_xml | – notice: Copyright © 2007 American Cancer Society – notice: 2008 INIST-CNRS – notice: Copyright (c) 2007 American Cancer Society. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1002/cncr.23073 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0142 |
EndPage | 2477 |
ExternalDocumentID | 17894390 19689911 10_1002_cncr_23073 CNCR23073 |
Genre | article Journal Article |
GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AGNAY AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M J5H JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NEJ NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ 3O- AAQOH AAYXX AEYWJ AGHNM AGYGG AI. CITATION EMOBN HF~ H~9 OHT RSU VH1 WHG Y6R YQJ ZXP AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c4233-d94f75a053d3611979cd25db96d8faa734db2992429ffafde59b7696bb5835f43 |
IEDL.DBID | DR2 |
ISSN | 0008-543X |
IngestDate | Sat Sep 27 21:39:22 EDT 2025 Mon Jul 21 06:05:00 EDT 2025 Mon Jul 21 09:11:54 EDT 2025 Thu Apr 24 22:55:18 EDT 2025 Tue Jul 01 01:22:07 EDT 2025 Wed Jan 22 16:34:56 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Chondrosarcoma Relapse Prognosis Sarcoma Diseases of the osteoarticular system skull base tumor Histology Malignant tumor Survival Osteoarticular system recurrence Cartilage Chordoma chondroid chordoma Cancerology Skull Bone outcome Cancer |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 Copyright (c) 2007 American Cancer Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4233-d94f75a053d3611979cd25db96d8faa734db2992429ffafde59b7696bb5835f43 |
Notes | Fax: (501) 686‐8767 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17894390 |
PQID | 68546806 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_68546806 pubmed_primary_17894390 pascalfrancis_primary_19689911 crossref_citationtrail_10_1002_cncr_23073 crossref_primary_10_1002_cncr_23073 wiley_primary_10_1002_cncr_23073_CNCR23073 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 1 December 2007 |
PublicationDateYYYYMMDD | 2007-12-01 |
PublicationDate_xml | – month: 12 year: 2007 text: 1 December 2007 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: New York, NY – name: United States |
PublicationTitle | Cancer |
PublicationTitleAlternate | Cancer |
PublicationYear | 2007 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
References | 1992; 184 2005; 131 1973; 32 1987; 72 1995; 36 2000; 88 2006; 58 2004; 68 2002; 33 2006; 59 1977; 40 1999; 23 2005; 63 1970; 53 2005 2003; 17 2003 1998; 65 2003; 179 1994; 101 1985; 17 1993; 78 1968; 19 1993; 17 2005; 440 2004; 16 1964; 17 1984; 8 2001; 12 1985; 56 1999; 91 1981; 52 2001; 95 1994; 74 1994; 4 2003; 23 2001; 10 e_1_2_5_26_2 e_1_2_5_27_2 e_1_2_5_24_2 e_1_2_5_25_2 e_1_2_5_22_2 e_1_2_5_23_2 e_1_2_5_20_2 e_1_2_5_21_2 e_1_2_5_28_2 e_1_2_5_29_2 e_1_2_5_41_2 e_1_2_5_14_2 e_1_2_5_37_2 e_1_2_5_13_2 e_1_2_5_38_2 e_1_2_5_9_2 e_1_2_5_16_2 e_1_2_5_35_2 e_1_2_5_8_2 e_1_2_5_15_2 e_1_2_5_36_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_33_2 e_1_2_5_6_2 e_1_2_5_34_2 e_1_2_5_5_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_4_2 e_1_2_5_11_2 e_1_2_5_32_2 e_1_2_5_3_2 e_1_2_5_2_2 e_1_2_5_18_2 e_1_2_5_17_2 e_1_2_5_39_2 Walker WP (e_1_2_5_19_2) 1994; 4 e_1_2_5_30_2 Harsh G (e_1_2_5_40_2) 2003 |
References_xml | – volume: 40 start-page: 818 year: 1977 end-page: 831 article-title: Prognostic factors in chondrosarcoma of bone publication-title: Cancer. – volume: 74 start-page: 2261 year: 1994 end-page: 2267 article-title: Base of skull chordoma. A correlative study of histologic and clinical features of 62 cases publication-title: Cancer. – volume: 58 start-page: 1090 year: 2006 end-page: 1098 article-title: Patient outcome at long‐term follow‐up after aggressive microsurgical resection of cranial base chondrosarcomas publication-title: Neurosurgery. – volume: 32 start-page: 410 year: 1973 end-page: 420 article-title: Chordomas and cartilaginous tumors at the skull base publication-title: Cancer. – volume: 17 start-page: 643 year: 1964 end-page: 656 article-title: Chordoma: an electron microscopic study publication-title: Cancer. – volume: 440 start-page: 209 year: 2005 end-page: 212 article-title: An institutional review of clear cell chondrosarcoma publication-title: Clin Orthop Relat Res. – volume: 56 start-page: 182 year: 1985 end-page: 187 article-title: Clinical and pathologic review of 48 cases of chordoma publication-title: Cancer. – volume: 179 start-page: 241 year: 2003 end-page: 248 article-title: Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure publication-title: Strahlenther Onkol. – volume: 16 start-page: 342 year: 2004 end-page: 354 article-title: Genetics of chondrosarcoma and related tumors publication-title: Curr Opin Oncol. – volume: 17 start-page: 703 year: 1985 end-page: 710 article-title: Cranial chordomas: clinical presentation and results of operative and radiation therapy in twenty‐six patients publication-title: Neurosurgery. – volume: 17 start-page: 738 year: 1993 end-page: 742 article-title: Cytogenetic findings in a metastasizing primary testicular chondrosarcoma publication-title: Am J Surg Pathol. – volume: 95 start-page: 933 year: 2001 end-page: 943 article-title: Chordomas of the craniocervical junction: follow‐up review and prognostic factors publication-title: J Neurosurg. – volume: 78 start-page: 741 year: 1993 end-page: 747 article-title: Intracranial chordomas: a clinicopathological and prognostic study of 51 cases publication-title: J Neurosurg. – volume: 58 start-page: 249 year: 2006 end-page: 255 article-title: Management of cranial base chondrosarcomas publication-title: Neurosurgery. – start-page: 80 year: 2003 end-page: 96 – volume: 59 start-page: 230 year: 2006 end-page: 237 article-title: Patient outcome at long‐term follow‐up after aggressive microsurgical resection of cranial base chordomas publication-title: Neurosurgery. – volume: 36 start-page: 887 year: 1995 end-page: 897 article-title: Chordomas and chondrosarcomas of the cranial base: results and follow‐up of 60 patients publication-title: Neurosurgery. – volume: 131 start-page: 333 year: 2005 end-page: 339 article-title: Dedifferentiated chondrosarcoma–a fatal disease publication-title: J Cancer Res Clin Oncol. – volume: 23 start-page: 1370 year: 1999 end-page: 1378 article-title: Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma publication-title: Am J Surg Pathol. – volume: 101 start-page: 36 year: 1994 end-page: 41 article-title: Chondroid chordoma–a variant of chordoma. A morphologic and immunohistochemical study publication-title: Am J Clin Pathol. – volume: 72 start-page: 229 year: 1987 end-page: 235 article-title: Does chondroid chordoma exist? publication-title: Acta Neuropathol (Berl). – volume: 68 start-page: 33 year: 2004 end-page: 39 article-title: Intracranial chondrosarcoma: a case report and review of the literature publication-title: J Neurooncol. – volume: 8 start-page: 443 year: 1984 end-page: 447 article-title: Enzyme histochemical characterization of chordomas publication-title: Am J Surg Pathol. – volume: 91 start-page: 432 year: 1999 end-page: 439 article-title: Proton radiation therapy for chordomas and chondrosarcomas of the skull base publication-title: J Neurosurg. – volume: 52 start-page: 49 year: 1981 end-page: 58 article-title: Chordoma. A clinicopathologic and prognostic study of a Swedish national series publication-title: Acta Orthopaed Scand. – start-page: 357 year: 2005 end-page: 365 – volume: 33 start-page: 188 year: 2002 end-page: 200 article-title: Cytogenetic aberrations and their prognostic impact in chondrosarcoma publication-title: Genes Chromosomes Cancer. – volume: 23 start-page: 995 year: 2003 end-page: 1009 article-title: Comprehensive review of intracranial chordoma publication-title: Radiographics. – volume: 10 start-page: E11 year: 2001 article-title: Review of skull base chordomas: prognostic factors and long‐term results of proton‐beam radiotherapy publication-title: Neurosurg Focus. – volume: 19 start-page: 327 year: 1968 end-page: 333 article-title: Cranial and intracranial cartilaginous tumours publication-title: Clin Radiol. – volume: 65 start-page: 88 year: 1998 end-page: 92 article-title: Intracranial chondrosarcoma: review of the literature and report of 15 cases publication-title: J Neurol Neurosurg Psychiatry. – volume: 53 start-page: 544 year: 1970 end-page: 551 article-title: The ultrastructure of chordoma publication-title: Am J Clin Pathol. – volume: 63 start-page: 401 year: 2005 end-page: 409 article-title: Results of spot‐scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience publication-title: Int J Radiat Oncol Biol Phys. – volume: 17 start-page: 318 year: 2003 end-page: 323 article-title: Visual complications of proton beam therapy for clival chordoma publication-title: Eye. – volume: 4 start-page: 661 year: 1994 end-page: 666 article-title: Immunohistochemical distinction of classic and chondroid chordomas publication-title: Mod Pathol. – volume: 88 start-page: 2181 year: 2000 end-page: 2188 article-title: Primary chondrosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 14 cases with a review of the literature publication-title: Cancer. – volume: 184 start-page: 103 year: 1992 end-page: 108 article-title: Chondrosarcomas of the skull base: MR imaging features publication-title: Radiology. – volume: 12 start-page: 1 year: 2001 end-page: 11 article-title: Chordoma: incidence and survival patterns in the United States, 1973–1995 publication-title: Cancer Causes Control. – volume: 10 start-page: E5 year: 2001 article-title: Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for residual or recurrent cranial base and cervical chordomas publication-title: Neurosurg Focus. – volume: 4 start-page: 661 year: 1994 ident: e_1_2_5_19_2 article-title: Immunohistochemical distinction of classic and chondroid chordomas publication-title: Mod Pathol. – ident: e_1_2_5_36_2 doi: 10.3109/17453678108991758 – ident: e_1_2_5_7_2 doi: 10.1227/01.NEU.0000194834.74873.FB – ident: e_1_2_5_2_2 – ident: e_1_2_5_13_2 doi: 10.1136/jnnp.65.1.88 – ident: e_1_2_5_23_2 doi: 10.3171/jns.1993.78.5.0741 – ident: e_1_2_5_26_2 doi: 10.1016/j.ijrobp.2005.02.023 – ident: e_1_2_5_39_2 doi: 10.1227/00006123-199505000-00001 – ident: e_1_2_5_21_2 doi: 10.1148/radiology.184.1.1609064 – ident: e_1_2_5_12_2 doi: 10.1016/S0009-9260(68)80019-4 – ident: e_1_2_5_8_2 doi: 10.1023/A:1008947301735 – ident: e_1_2_5_29_2 doi: 10.3171/foc.2001.10.3.6 – ident: e_1_2_5_16_2 doi: 10.1097/00000478-199911000-00007 – ident: e_1_2_5_20_2 doi: 10.1148/rg.234025176 – ident: e_1_2_5_17_2 doi: 10.1097/00000478-198406000-00005 – ident: e_1_2_5_5_2 doi: 10.1016/B978-0-7216-8148-1.50051-6 – ident: e_1_2_5_14_2 doi: 10.1023/B:NEON.0000024728.72998.7d – ident: e_1_2_5_37_2 doi: 10.1002/1097-0142(19850701)56:1<182::AID-CNCR2820560131>3.0.CO;2-J – ident: e_1_2_5_22_2 doi: 10.1002/1097-0142(19941015)74:8<2261::AID-CNCR2820740809>3.0.CO;2-0 – ident: e_1_2_5_41_2 doi: 10.1227/01.NEU.0000223441.51012.9D – ident: e_1_2_5_28_2 doi: 10.1038/sj.eye.6700339 – ident: e_1_2_5_11_2 doi: 10.1002/(SICI)1097-0142(20000501)88:9<2181::AID-CNCR26>3.0.CO;2-6 – ident: e_1_2_5_34_2 doi: 10.1097/01.blo.0000174686.70003.e0 – ident: e_1_2_5_38_2 doi: 10.1227/00006123-198511000-00002 – ident: e_1_2_5_32_2 doi: 10.1097/01.cco.0000129678.72521.e5 – ident: e_1_2_5_31_2 doi: 10.1097/00000478-199307000-00012 – ident: e_1_2_5_4_2 doi: 10.1093/ajcp/101.1.36 – ident: e_1_2_5_9_2 doi: 10.1093/ajcp/53.4.544 – start-page: 80 volume-title: Chordomas and Chondrosarcomas of the Skull Base and Spine year: 2003 ident: e_1_2_5_40_2 – ident: e_1_2_5_18_2 doi: 10.1007/BF00691094 – ident: e_1_2_5_6_2 doi: 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B – ident: e_1_2_5_33_2 doi: 10.1007/s00432-004-0648-6 – ident: e_1_2_5_24_2 doi: 10.3171/foc.2001.10.3.12 – ident: e_1_2_5_10_2 doi: 10.1002/1097-0142(196405)17:5<643::AID-CNCR2820170513>3.0.CO;2-Q – ident: e_1_2_5_27_2 doi: 10.3171/jns.1999.91.3.0432 – ident: e_1_2_5_3_2 doi: 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S – ident: e_1_2_5_15_2 doi: 10.3171/jns.2001.95.6.0933 – ident: e_1_2_5_30_2 doi: 10.1227/01.NEU.0000215892.65663.54 – ident: e_1_2_5_35_2 doi: 10.1002/gcc.10012 – ident: e_1_2_5_25_2 doi: 10.1007/s00066-003-1065-5 |
SSID | ssj0007253 |
Score | 2.3554664 |
Snippet | BACKGROUND
Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic... Chordoma and chondrosarcoma of the skull base are frequently amalgamated because of similar anatomic location, clinical presentation, and radiologic findings.... |
SourceID | proquest pubmed pascalfrancis crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2467 |
SubjectTerms | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Child Child, Preschool chondroid chordoma chondrosarcoma Chondrosarcoma - diagnosis Chondrosarcoma - pathology Chondrosarcoma - radiotherapy Chondrosarcoma - surgery chordoma Chordoma - diagnosis Chordoma - pathology Chordoma - radiotherapy Chordoma - surgery Diseases of the osteoarticular system Female histology Humans Infant Male Medical sciences Middle Aged Neoplasm Recurrence, Local outcome recurrence Retrospective Studies Skull Base Neoplasms - diagnosis Skull Base Neoplasms - pathology Skull Base Neoplasms - radiotherapy Skull Base Neoplasms - surgery skull base tumor survival Treatment Outcome Tumors Tumors of striated muscle and skeleton |
Title | Chordoma and chondrosarcoma: Similar, but quite different, skull base tumors |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.23073 https://www.ncbi.nlm.nih.gov/pubmed/17894390 https://www.proquest.com/docview/68546806 |
Volume | 110 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS-RAEC7EBxGW9djDeG3D-qIYZyZHJy2-yOyKLKsPHjAvS-iTFXcyOkle_PVWd5IJIyK4byFU5-iq6vqqj68A9rhGWMCU8DH6RH5keOJzDBS-Za8KdIiIIrCHky8u6flt9GsUjxbgpD0LU_NDzCbcrGe48do6OBdFryMNlbmcum3MlupzEFJLnP_jquOOSoKGgrKf-nEUjmbcpEGvazoXjT488AI7xtQVLV6DnPMI1oWgsxX40358vfPk_qgqxZF8esHr-L9_twofG2xKTmtjWoMFna_D0kWz-v4Jfg__Yqo6GXPCc0Vw3LRkBwV6Ct46Jtd34ztMkw-JqEryWCGUJW31lfKQFPeY6xIbM0lZjSfT4jPcnv28GZ77TTUGXyLkCn3FIpPEHJ1WhdQuPjKpglgJRlVqOE_CSAmMbRjymTHcKB0zkVBGhYgR5Zko_AKL-STXG0D6ItRaJPYxEs0jTTGKpgyxJlNGUio92G-1ksmGqtxWzPiX1STLQWa7J3Pd48H3mexDTdDxqtTunHI7UUYx4xwMPPjWajtDB7OrJjzXk6rIaBpHNO1TD77WRtC1TSx5Pet7cOBU-cb7s-Hl8Mpdbb5HeAuW3Vyy2z6zDYvltNI7CIJKseuM_Rkx5gE1 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED8xkLZJCNgGI8DA0vayiUDJhxPzhqqhAm0fGEh9i_wpEGvKmuSFv56zkzbqhCaxtyiyY8V35_vZd_4dwDeuERYwJXz0PpEfGZ74HB2Fb9mrAh0iogjs5eTBkPZuo8tRPGpyc-xdmJofYn7gZi3DrdfWwO2B9HHLGipzOXV5zOEbWHEBOouJrlv2qCRoSCg7qR9H4WjOThoct30X_NHqIy9wakxd0-Il0LmIYZ0TOl-vK60WjrvQ5p48HFWlOJJPfzE7_vf_bcBaA0_JWa1PH2BJ5x_h7aAJwH-CfvcOd6uTMSc8VwSXTst3UKCx4KtT8ut-fI875UMiqpL8qRDNklkBlvKQFA84MrFuk5TVeDItNuH2_OdNt-c3BRl8iagr9BWLTBJztFsVUht_ZFIFsRKMqtRwnoSREuje0OszY7hROmYioYwKESPQM1G4Bcv5JNfbQDoi1Fok9jMSNSRN0ZGmDOEmU0ZSKj34PhNLJhu2cls043dW8ywHmZ2ezE2PB1_nbR9rjo4XW-0vSLdtyihuOk9OPDiYiTtDG7OBE57rSVVkNI0jmnaoB59rLWj7Jpa_nnU8-OFk-Y_xs-6we-2edl7T-ADe9W4G_ax_MbzahffuaNll0-zBcjmt9BfERKXYd5r_DELYBVM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFD7UCkWQ1nvjpR3QF6Vpt8lkkim-yOpStV2kWtiXEuaKpd3sdpO8-Os9M0k2rBRB30KYyWXOOfN9Zy7fALwRBmkB1zJE9KEhtSINBQJF6NSrIhMjo4jc5uTTMTs-p18myWQN3nd7YRp9iOWAm4sM31-7AJ9re9CLhqpCLfwy5vgO3KUMcdJRorNePCqNWg3KQRYmNJ4sxUmjg77uChzdn4sSW8Y2R1rcxjlXKazHoNEWXHRf3yw9udqvK7mvfv0h7Pi_v_cANltySj403vQQ1kzxCDZO2-n3x3Ay_Im56mwqiCg0wY7TqR2UGCp464h8v5xeYp68R2RdkZsauSzpjl-p9kh5hckucaBJqno6W5RP4Hz06cfwOGyPYwgVcq441JzaNBEYtTpmbvaRKx0lWnKmMytEGlMtEdwQ87m1wmqTcJkyzqRMkOZZGj-F9WJWmG0gAxkbI1P3GIX-kWUIoxlHssm1VYypAN52VslVq1Xujsy4zhuV5Sh3zZP75gng9bLsvFHouLXUzopx-6KcYcp5eBjAbmftHCPMTZuIwszqMmdZQlk2YAE8a5ygr5s69Xo-COCdN-Vf3p8Px8Mzf_X8Xwrvwsa3j6P85PP46wu458eV_VKal7BeLWrzCglRJXe83_8GM9MEAg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chordoma+and+chondrosarcoma+%3A+Similar%2C+but+quite+different%2C+skull+base+tumors&rft.jtitle=Cancer&rft.au=ALMEFTY%2C+Kaith&rft.au=PRAVDENKOVA%2C+Svetlana&rft.au=COLLI%2C+Benedicto+O&rft.au=AL-MEFTY%2C+Ossama&rft.date=2007-12-01&rft.pub=Wiley-Liss&rft.issn=0008-543X&rft.volume=110&rft.issue=11&rft.spage=2457&rft.epage=2467&rft_id=info:doi/10.1002%2Fcncr.23073&rft.externalDBID=n%2Fa&rft.externalDocID=19689911 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |